WAMU 88.5 : News

Filed Under:

Track Work On Orange, Red Through Columbus Day

Play associated audio
Metro is telling riders to expect extra travel times through Columbus Day.
Scott Pitocco: http://www.flickr.com/photos/lightsoutphotos/4331800230/
Metro is telling riders to expect extra travel times through Columbus Day.

Metro is planning to use the Columbus Day holiday Monday for an extra day of weekend track maintenance.

The work gets underway at 10 p.m. Friday night and will affect service on the Red and Orange lines.

Red Line trains will share a single track all weekend between Judiciary Square and Fort Totten. Metro says anyone headed through that stretch can expect it to take up to 20 minutes longer than usual. Red Line passengers on the western leg and through downtown can expect 10 minute delays.

Meanwhile, Orange Line trains will be single tracking between Stadium-Armory and Cheverly. Metro says anyone traveling to or from stations east of Stadium-Armory should figure on 15 minutes of additional travel time.

The work will continue through Columbus Day on Monday. Service should return to normal on Tuesday morning.

NPR

Misty Copeland Inspires A Barbie 'Sheroes' Doll

Misty Copeland says she played with Barbie dolls until she was 13 — the same year she started ballet.
NPR

'Touch Tours' Help Blind Experience Philadelphia's Historic Food Scene

A hands-on tour of Philadelphia's historic Italian Market includes time to appreciate the scents and sounds — and opportunities to sample the district's delicious chocolate, cheeses and fresh pastas.
WAMU 88.5

Shaking Up Metro's Board

After another smoke incident and ongoing single tracking delays for fixes, U.S. Secretary of Transportation Anthony Foxx replaced three Metro board members with safety experts, while a Maryland Congressman introduced legislation which would require the next three federally appointed Metro board members have relevant expertise.

NPR

Biotech's Theranos Offers A Cautionary Tale For Silicon Valley

The blood-testing startup led by Elizabeth Holmes soared on hype and celebrity boosters. Now it's under federal scrutiny. It could show that Silicon Valley's success model doesn't work in biotech.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.